Traditional Chinese medicine and lung cancer--From theory to practice.
Adjuvant therapy
Immunotherapy
Lung cancer
Traditional Chinese medicine
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
24
10
2020
revised:
04
02
2021
accepted:
08
02
2021
pubmed:
19
2
2021
medline:
17
7
2021
entrez:
18
2
2021
Statut:
ppublish
Résumé
With the continuous breakthroughs in molecular biology and biochemistry, we have constantly made great progress in the treatment of lung cancer. There is no doubt that standard treatment (such as surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy) has greatly improved the prognosis of lung cancer populations. In particular, the immunotherapy has brought more and more good news to countless lung cancer patients. In contrast to these standard treatments, traditional Chinese medicine (TCM) rarely has a profound and comprehensive overview in the field of lung cancer. This article will summarize the latest progress of TCM in lung cancer which is mainly non-small cell lung cancer (NSCLC) from theory to clinical practice, which would carry forward the sophisticated TCM and promote the development of modern medicine.
Identifiants
pubmed: 33601147
pii: S0753-3322(21)00166-9
doi: 10.1016/j.biopha.2021.111381
pii:
doi:
Substances chimiques
Drugs, Chinese Herbal
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
111381Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.